A Case-Based Discussion of Clinical Problems in the Management of Patients Treated With Ruxolitinib for Myelofibrosis
There is now increasing and extensive experience of the efficacy and safety of ruxolitinib in patients with myelofibrosis (MF), both in clinical trials and in 'real-world' practice. The drug has been shown to be of benefit in intermediate-1 risk patients with symptomatic splenomegaly or other MF-related symptoms, and higher risk disease. This paper aims to utilize several 'real-life' cases to illustrate several strategies that may help to optimize clinical practice.
Intern Med J
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology